Author

Tongchen He

University of Michigan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5 Molecular Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Research Focus:cancer & tumor microenvironment· 5 Organism:human· 4 Organism:mouse· 3 Assay:bulk RNA-seq· 2 Assay:ChIP-seq· 2 Research Focus:gene regulatory network inference· 2 Assay:proteomics· 2

Frequent Co-Authors

Arul M. ChinnaiyaniD· 5 shared Lanbo XiaoiD· 5 shared Xuhong CaoiD· 5 shared Yuanyuan QiaoiD· 5 shared Abhijit ParoliaiD· 4 shared Fengyun SuiD· 4 shared Rahul MannaniD· 4 shared Somnath MahapatraiD· 4 shared

Activity by Year

2024-2026 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersCancer Biology

Arul M. ChinnaiyanORCID

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Divergent condensates tune transcriptional responses during stress

Jeffrey N. Dudley, Joel E. Berends, Chayan K. De, Tongchen He, Giovana M. B. Veronezi, Benedict Abdon, Anjali Sengar, Matthias C. Truttmann, Mats E. Ljungman, Lanbo Xiao, Srinivas Ramachandran, Sethuramasundaram Pitchiaya

This study shows that HSF1 forms stress-induced condensates with divergent transcriptional outcomes, impacting transcriptional responses during different stress conditions.

bioRxiv · Feb 13, 2026 · PreprintMolecular Biology

p300/CBP degradation is required to disable the active AR enhanceosome in prostate cancer

Jie Luo, Zhixiang Chen, Yuanyuan Qiao, Jean Ching-Yi Tien, Eleanor Young, Rahul Mannan, Somnath Mahapatra, Rupam Bhattacharyya, Lanbo Xiao, Tongchen He, Sanjana Eyunni, Yuping Zhang, Yang Zheng, Fengyun Su, Xuhong Cao, , Arul M. Chinnaiyan

This study shows that degrading p300/CBP in prostate cancer suppresses tumor growth more effectively than inhibiting their activity, highlighting their role in maintaining the active AR enhanceosome.

Nature Genetics · Oct 1, 2025Peer-reviewedCancer Biology

Targeting PIKfyve-driven lipid homeostasis as a metabolic vulnerability in pancreatic cancer

Caleb Cheng, Jing Hu, Rahul Mannan, Tongchen He, Rupam Bhattacharyya, Brian Magnuson, Jasmine P. Wisniewski, Sydney Peters, Saadia A. Karim, David MacLean, Hüseyin Karabürk, Li Zhang, Nicholas J. Rossiter, Yang Zheng, Lanbo Xiao, , Arul M. Chinnaiyan

This study identifies PIKfyve as a targetable vulnerability in pancreatic cancer by showing its role in lipid metabolism and synthetic lethality with KRAS-MAPK inhibitors.

Nature · Apr 23, 2025Peer-reviewedCancer Biology

NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis

Abhijit Parolia, Sanjana Eyunni, Brijesh Kumar Verma, Eleanor Young, Yihan Liu, Lianchao Liu, James M. George, Shweta Aras, Chandan Kanta Das, Rahul Mannan, Reyaz ur Rasool, Erick Mitchell-Velasquez, Somnath Mahapatra, Jie Luo, Sandra E. Carson, , Irfan Ahmed Asangani

This study identifies NSD2 as a critical component of the AR neo-enhanceosome in prostate cancer, showing its role in AR enhancer circuitry and tumor progression.

Nature Genetics · Sep 9, 2024Peer-reviewedCancer Biology

PIKfyve controls dendritic cell function and tumor immunity

Jae Eun Choi, Yuanyuan Qiao, Ilona Kryczek, Jiali Yu, Jonathan K. Gurkan, Yi Bao, Mahnoor Naseer Gondal, Jean Ching-Yi Tien, Tomasz Maj, Sahr Yazdani, Abhijit Parolia, Houjun Xia, Jiajia Zhou, Shuang Wei, Sara Grove, , Arul M. Chinnaiyan

This study shows that PIKfyve inhibition enhances dendritic cell function and improves immunotherapy efficacy in tumor models.

Nature Communications · Jun 28, 2024Peer-reviewedCancer Biology

Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer

Tongchen He, Caleb Cheng, Yuanyuan Qiao, Hanbyul Cho, ELEANOR A. YOUNG, Rahul Mannan, Somnath Mahapatra, Stephanie J. Miner, Yang Zheng, Nam Hoon Kim, Victoria Zhixuan Zeng, Jasmine P. Wisniewski, Siyu Hou, Bailey Jackson, Xuhong Cao, , Arul M. Chinnaiyan

This paper develops an orally bioavailable PROTAC degrader of mSWI/SNF ATPases for prostate cancer and identifies resistance mechanisms through long-term treatment.

Proceedings of the National Academy of Sciences · Apr 1, 2024Peer-reviewedCancer Biology